{"id":5941,"date":"2025-03-16T15:26:55","date_gmt":"2025-03-16T12:26:55","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5941"},"modified":"2025-03-16T15:26:55","modified_gmt":"2025-03-16T12:26:55","slug":"tavr-linked-to-stronger-valve-performance-than-savr-in-new-5-year-study","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/tavr-linked-to-stronger-valve-performance-than-savr-in-new-5-year-study\/","title":{"rendered":"TAVR Linked to Stronger Valve Performance Than SAVR in New 5-Year Study"},"content":{"rendered":"<div>JACC. March 9, 2025<\/div>\n<div><\/div>\n<div>TAVR Linked to Stronger Valve Performance Than SAVR in New 5-Year Study<\/div>\n<div><\/div>\n<div>Key Points: TAVR vs. SAVR in 5-Year Valve Performance Study<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Study Overview: New data from over 5,600 patients show that TAVR results in lower bioprosthetic valve dysfunction (BVD) rates than SAVR at five years.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Data Sources: Included both RCT patients (41%) and non-RCT patients from CoreValve trials.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Patient Demographics: Mean age 82.2 years, 45.2% women; all TAVR patients received Medtronic CoreValve\/Evolut valves.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>BVD Rates:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>TAVR: 9.7% in RCT patients.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>SAVR: 15.3% in RCT patients.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>BVD Definition: Included structural and non-structural deterioration, thrombosis with clinical impact, and infectious endocarditis.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Clinical Impact: BVD is associated with a higher risk of all-cause mortality, cardiovascular mortality, and hospitalization for valve disease\/heart failure over five years.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Key Conclusion: This is the first study to validate clinical BVD criteria and confirm a \u226550% increased five-year risk of death or hospitalization in affected patients.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Future Outlook: A 10-year follow-up is ongoing. Findings highlight TAVR\u2019s superior valve durability as a key factor in valve selection for patients with severe AS.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Funding: Study sponsored by Medtronic, which also funded the SMART trial on long-term BVD risks.<\/div>\n<div><\/div>\n<div>Read more<\/div>\n<div><\/div>\n<div>Also of Interest:<\/div>\n<div><\/div>\n<div>Early TAVR or SAVR for Asymptomatic Severe AS Limits Strokes, Hospitalizations<\/div>\n<div>Published: March 7, 2025<\/div>\n<div>Read full text<\/div>\n","protected":false},"excerpt":{"rendered":"<p>JACC. March 9, 2025 TAVR Linked to Stronger Valve Performance Than SAVR in New 5-Year Study Key Points: TAVR vs. SAVR in 5-Year Valve Performance Study \u2022 Study Overview: New data from over 5,600 patients show that TAVR results in lower bioprosthetic valve dysfunction (BVD) rates than SAVR at five years. \u2022 Data Sources: Included [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5941","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5941"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5941\/revisions"}],"predecessor-version":[{"id":5942,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5941\/revisions\/5942"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}